To address the limitations associated with conventional therapies and naked mAb-based immunotherapy, recombinant ADCs were developed in the form of scFv–SNAP-tag fusion proteins conjugated to MMAF endowed with the ability to specifically detect and kill melanoma and other cancer cells overexpressing EGFR using nano and picomolar concentrations [242,243]. This evidence concerns the gene EGFR and melanoma.